19771-63-2

Basic information

• Product Name: Procysteine
• Synonyms: (4R)-2-Oxothiazolidine-4-carboxylic acid;(4R)-2-Oxothiazolidine-4α-carboxylic acid;(4R)-2-ketothiazolidine-4-carboxylic acid;L-Thiazolidin-2-one-4-carboxylic acid, OTC, Procysteine, OTZ;Oxothiazolidine carboxylate;L-2-Thiazolidinone-4-carboxylic Acid,L-2-Oxothiazolidine-4-carboxylic Acid;4-Thiazolidinecarboxylicacid, 2-oxo-, (4R)-;L-2-Thiazolidinone-4-carboxylic Acid
• CAS NO: 19771-63-2
• Molecular Formula: C₄H₅NO₃S
• Molecular Weight: 147.15
• EINECS: 200-154-8
• Product Categories: whitening and anti-aging material and other functions in cosmetics;CARBOXYLICACID
• Mol File: 19771-63-2.mol
• Article Data: 8

Chemical Properties

• Melting Point: 174 °C (dec.)(lit.)
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: White to Off-white/Powder
• Density: 1.582 g/cm³
• Refractive Index: -64 ° (C=1, H2O)
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly), Water (Slightly)
• PKA: pKa (22°): 3.32
• Water Solubility: Soluble in water
• Merck: 13,7019
• BRN: 4179169
• CAS DataBase Reference: Procysteine(CAS DataBase Reference)
• NIST Chemistry Reference: Procysteine(19771-63-2)
• EPA Substance Registry System: Procysteine(19771-63-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• RTECS: XJ5426650
• Hazardous Substances Data: 19771-63-2(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

Uses

(R)-(-)-2-Oxothiazolidine-4-carboxylic Acid or Procysteine is a precursor to glutathione (GSH) which is an important antioxidant in plants, animals and fungi.

InChI:InChI=1/C4H5NO3S/c6-3(7)2-1-9-4(8)5-2/h2H,1H2,(H,5,8)(H,6,7)/t2-/m0/s1

Upstream product

• 55694-10-5 2-Oxo-thiazolidine-4-carboxylic acid ethyl ester 
• 52-90-4 L-Cysteine 
• 52-89-1 l-cysteine hydrochloride 
• 1885-14-9 phenyl chloroformate 
• 127761-77-7 L-2-oxothiazolidine-4-carboxylic acid methyl ester 
• 75-44-5 phosgene 
• 32315-10-9 bis(trichloromethyl) carbonate 

Downstream Products

• 781648-29-1 tetrahydrothiazolo[3,4-a]pyrazine-3,5,8-trione 
• 98155-23-8 (R)-3-benzyl-2-oxothiazolidine-4-carboxylic acid 
• 98155-24-9 (R)-2-oxothiazolidine-4-carboxylic acid ethyl ester 
• 143397-35-7 (R)-4-acetyl-2-oxothiazolidine 
• 127761-77-7 L-2-oxothiazolidine-4-carboxylic acid methyl ester 
• 702672-64-8 (4R)-N-[3-[[5-bromo-2-[[3-(2,5-dioxo-1-imidazolidinyl)phenyl]amino]-5-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide 
• 702677-62-1 (4R)-N-[3-[[5-bromo-2-[[3-[2,5-dioxo-3-[[(4R)-2-oxo-4-thiazolidinyl]carbonyl]-1-imidazolidinyl]phenyl]amino]-4-pyrimidinyl]amino]propyl]-2-oxo-4-thiazolidinecarboxamide 

Related news

Clinical Investigations in Critical Care: ArticlesA Trial of Antioxidants N-acetylcysteine and Procysteine (cas 19771-63-2) in ARDS09/04/2019

ObjectiveTo determine the levels of glutathione and cysteine in patients with ARDS and examine the effect of treatment with N-acetylcysteine (NAC) and L-2-oxothiazolidine-4-carboxylate (Procysteine; Clintec Technologies Inc; Chicago [OTZ]) on these levels and on common physiologic abnormalities,...detailed

Research communicationProtection of the ischemic rat heart by Procysteine (cas 19771-63-2) and amino acids☆09/02/2019

This study was conducted to determine the efficacy of amino acids and/or Procysteine (Clintec Technologies, Inc., Deerfield, IL, USA) on the recovery of cardiac function of the rat heart subjected to ischemia/reperfusion. Recovery of myocardium following ischemia/reperfusion is affected by both ...detailed

Relevant articles and documents

AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.

Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinson's disease

Parkinson's disease (PD) is one of the major debilitating neurodegenerative disorders affecting millions of people worldwide. Progressive loss of dopamine neurons resulting in development of motor dysfunction and other related non-motor symptoms is the hallmark of PD. Previously, we have reported on the neuroprotective property of a potent D3 preferring agonist D-264. In our goal to increase the bioavailability of D-264 in the brain, we have synthesized a modified cysteine based prodrug of D-264 and evaluated its potential in crossing the blood-brain barrier. Herein, we report the synthesis of a novel modified cysteine conjugated prodrug of potent neuroprotective D3 preferring agonist D-264 and systematic evaluation of the hydrolysis pattern of the prodrug to yield D-264 at different time intervals in rat plasma and brain homogenates using HPLC analysis. Furthermore, we have also performed in vivo experiments with the prodrug to evaluate its enhanced brain penetration ability.

A practical synthesis of (+)-biotin from L-cysteine

α-Amino aldehyde 4, which is readily derived from L-cysteine through cyclization and elaboration of the carboxy group, was subjected to the Strecker reaction, which, via sodium bisulfite adduct 16, afforded α-amino nitrile 5 with high diastereose-lectivity (syn/anti = 11:1) and in high yield. Amide 6, derived from 5, was converted to thiolactone 8, a key intermediate in the synthesis of (+)-biotin (1), by a novel S,N-carbonyl migration and cyclization reaction. The Fukuyama coupling reaction of 8 with the zinc reagent 21, which has an ester group, in the presence of a heterogeneous Pd/ C catalyst allowed the efficient installation of the 4-carboxybutyl chain to provide 9. Compound 9 was hydrogenated and the protecting groups removed to furnish 1 in 10 steps and in 34 % overall yield from L-cysteine.